BDX Stock Analysis — Becton Dickinson
Sector: Healthcare
AI Verdict
BDX trades at just 11.2x forward earnings with sky-high growth expectations, so if the moat-driven recurring revenue delivers, this is cheap for the growth on offer — but the overbought RSI means short-term downside is a real risk.
Competitive Moat
Becton Dickinson dominates the medical devices and consumables market with deep hospital integration and regulatory expertise, making it costly and risky for hospitals to switch suppliers. Its broad product portfolio and embedded distribution relationships create high switching costs and recurring revenue streams.
Summary
A massive jump in forward earnings expectations has slashed BDX's forward P/E to 11.2x, making it unusually cheap for a medtech giant.
Where It Stands
BDX has delivered a 10.82% 1-year return, trades at 11.2x next year's earnings (well below the healthcare sector median of 22x), but its RSI of 73.0 signals overbought territory and pullback risk.
Key Metrics
- RSI: 73 — Overbought
- Trailing P/E: 38.4x
- Forward P/E: 11.2x
- PEG Ratio: 0.16
- Earnings Growth: +2.4%
- Revenue Growth: +0.0%
- Market Cap: $41.7B
- Dividend Yield: 0.03%
- 1-Year Return: 10.82%
- 52-Week High: $187.35
- 52-Week Low: $127.59
Analyst Consensus
9 Buy · 12 Hold · 0 Sell (21 analysts)
Bull Case
With analysts forecasting 242.0% EPS growth next year, the current 11.2x forward P/E is cheap for the explosive earnings rebound expected.
Bear Case
An RSI of 73.0 means the stock is overbought, so even a normal pullback to a neutral RSI could erase much of the recent 10.82% 1-year gain.
Catalyst to Watch
Watch the next quarterly earnings for confirmation that the 242.0% EPS growth materializes — a miss would likely trigger a sharp rerating.